Aim immunotech reports positive pilot study data from expanded access program evaluating ampligen® for the treatment of long covid

Growing body of data supports investigational new drug (“ind”) application with the u.s. food and drug administration (“fda”) for a phase 2 study of ampligen for the treatment of post-covid conditions growing body of data supports investigational new drug (“ind”) application with the u.s. food and drug administration (“fda”) for a phase 2 study of ampligen for the treatment of post-covid conditions
AIM Ratings Summary
AIM Quant Ranking